High-Dose Anticoagulation Reduces Intubations, Improves COVID-19 Survival miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
In conducting the “Statins to Prevent the Cardiotoxicity from Anthracyclines: The STOP-CA Trial,” researchers found that among people receiving chemotherapy regimens containing anthracyclines for lymphoma, those who took the cholesterol-lowering drug atorvastatin for one year were significantly less likely to show evidence of heart dysfunction than those who took a placebo. FIndings were reported during the first late-breaking clinical trial session during the March 4-6 American College of Cardiology’s Annual Scientific Session Together with the World Congress of Cardiology, ACC.23/WCC.
Findings from the TRILUMINATE Pivotal trial found no significant difference in survival or hospitalization after one year of follow-up, according to research presented on the first day of the American College of Cardiology’s Annual Scientific Session Together with the World Congress of Cardiology, ACC.23/WCC. The study did find that in patients with a poorly functioning tricuspid valve in the heart, a minimally invasive procedure using a clip to repair the valve was safe and improved both the valve’s functioning and patients’ quality of life at one year compared with the best available medical therapy.
Of the immense volume of valuable information offered and exchanged during the first day of the American College of Cardiology's Annual Scientific Session Together with the World Congress of Cardiology, ACC.23/WCC, the DAIC editorial team has selected a sampling of session highlights from our notebooks of top ACC.23/WCC news.
Results of the CLEAR Outcomes trial, presenting during the American College of Cardiology's Annual Scientific Session Together with the World Congress of Cardiology, ACC.23/WCC, were presented during the event's first late-breaking clinical trial session in New Orleans, LA. The study found Bempedoic Acid lowered cholesterol and reduced the risk of serious cardiovascular outcomes in statin-intolerant patients.